Strand Therapeutics Inc.
Clinical trials sponsored by Strand Therapeutics Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New RNA shot directly into tumors could boost immune attack Results expected May 2027 (estimated)
-
Can an mRNA therapy supercharge the immune system against cancer?
Disease control Recruiting nowThis trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…
Phase 1/2 • Sponsor: Strand Therapeutics Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New RNA shot directly into tumors could boost immune attack
Disease control Recruiting nowThis early-phase trial tests a new drug called STX-001, a self-replicating RNA that makes a protein to stimulate the immune system. It is injected directly into tumors, either alone or with the immunotherapy pembrolizumab (Keytruda). The study aims to find a safe dose and see if …
Phase 1/2 • Sponsor: Strand Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC